Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Biotechnology Venture Capital Valuations Provides Best Practices for Venture Capitalists and Entrepreneurs at All Stages of Investment.


DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37151) has announced the addition of Biotechnology Venture Capital Valuations: Leading VCs on Deal Structures, Negotiations, and Best Practices for Current and Future Rounds of Financing to their offering.

Biotechnology Venture Capital Valuations is an authoritative, insider's perspective on biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 venture capital for both the venture capitalist Venture Capitalist

An investor who provides capital to either start-up ventures or support small companies who wish to expand but do not have access to public funding.

Notes:
Venture capitalists usually expect higher returns for the additional risks taken.
 and the entrepreneur. Featuring partners, presidents, and CEOs of top venture capital and investment firms, Biotechnology Venture Capital Valuations provides best practices for venture capitalists and entrepreneurs at all stages of investment with a focus on determining valuations and structuring deals. These industry experts discuss their strategies for considering a biotech investment, locating investment opportunity, assessing risk, and negotiating with the entrepreneur, as well as offering different valuation methods for a variety of common scenarios. This book provides valuable insight for those investing capital as well as those needing it, including explanation of the different goals of the venture capitalist and entrepreneur, common mistakes made on both sides, and how best to establish a productive relationship between the two. Entrepreneurs seeking to secure financing will benefit from the authors' advice on how to determine the target amount of capital, how to approach an initial meeting, and how to increase the chances of higher valuation. The different niches presented and the breadth of perspectives represented enable readers to get inside some of the leading minds of today, as these insiders offer up their thoughts around the keys to successful investment within this rapidly growing industry.

Contents are as follows:-

1. Frederick R. Blume, Partner, CB Health Ventures, "A Venture Capitalist's Advice to Biotech Entrepreneurs: Guidance on How to Secure Financing for Your Enterprise"

2. Charlotte P. Clark, Managing Partner, POSCO POSCO Pohang Iron & Steel Co, Ltd  BioVentures, "Venture Capital in the Biotech Industry"

3. Jonathan J. Fleming, General Partner, Oxford Bioscience bioscience /bio·sci·ence/ (-si´ens) the study of biology wherein all the applicable sciences (physics, chemistry, etc.) are applied.

bi·o·sci·ence
n.
See life science.
 Partners, "Biotech Venture Capital: A Look Back and a Look Ahead"

4. William Kieger, President, Aurora Aurora, cities, United States
Aurora (ərôr`ə, ô–).

1 City (1990 pop. 222,103), Adams and Arapahoe counties, N central Colo., a growing suburb on the east side of Denver; inc. 1903.
 Capital Group, "Assembling the Pieces of a Successful Deal"

5. A. Dana Callow Jr., General Partner, Boston Millenia Partners, "Early-Stage Health Care Investing: The Core Company Approach"

6. Alfred ("Buz") Brown, Ph.D., President, BCM BCM Baylor College of Medicine
BCM Become
BCM Business Communications Manager (Nortel)
BCM Broadcom Corporation
BCM Business Continuity Management
BCM Business Contact Manager (Microsoft) 
 Technologies Inc., "Locating and Investing in Biotech Opportunities"

7. T. Forcht Dagi, M.D., Managing Partner, Cordova Cordova, Spain: see Córdoba.  Ventures, "Relationships, Skills, and a Little Bit of Luck"

8. Christine D. Copple, Ph.D., President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Starise Ventures Inc., "Biotech Venture Capital: A Contact Sport."

For more information visit http://www.researchandmarkets.com/reports/c37151
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 18, 2006
Words:405
Previous Article:Second Intergraph Z/I Imaging DMC Purchased by Cartographic Institute of Catalonia; Overwhelming Success of First DMC Prompts Purchase of an...
Next Article:Secure Computing Honors Leading North American Companies with Partners of Excellence Awards.
Topics:



Related Articles
The Ideal Physician EntrePreneur.
How to help your client's business win venture capital.
Mining venture capital: to gain financing today, use the right tools or get the shaft. (Business Opportunities).
Is your VC a vulture capitalist? Entrepreneurs should do their homework before signing with a financier. (Capital Matters).
Venture capital forecast: hot with a chance of storms; The venture capital market has come back strongly from its lows in 2001, but concerns linger...
Plugging the funding gap.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles